Manjiri Pawaskar
Biographic Data
| ID | 9064945 |
|---|---|
| NAME | Manjiri Pawaskar |
| GIVEN NAMES | Manjiri |
| FAMILY NAME | Pawaskar |
| SIGNATURE | PAWASKAR M |
| AFFILIATIONS | Merck & Co., Inc., Rahway, NJ, USA (United States) |
| ORCID | 0000-0001-8009-805X |
| VERIFIED | No |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Modeling the clinical and economic impact of universal varicella vaccination in Belgium with dynamic population
Although universal varicella vaccination (UVV) significantly reduces morbidity and mortality, it has not been implemented in Belgium. We evaluated the clinical and economic outcomes of two-dose UVV in Belgium. A previously published dynamic transmission model with dynamic population age structure was adapted to Belgium. The base case UVV strategy (Strategy 0) consisted of routine two-dose varicella vaccination at ages 1 year (vaccine coverage rat…
Economic burden of varicella in Bangkok, Thailand
Our multicenter, medical chart review, cost-of-illness study used a micro-costing approach to evaluate the economic burden associated with varicella in Bangkok, Thailand, from a societal perspective. We reviewed medical charts of adults and children with a primary diagnosis of varicella (2014–2018) from 4 hospitals in Bangkok. Reported healthcare resource utilization and missed school or workdays were extracted from medical charts. Mean direct, i…
Universal varicella vaccination in Denmark
We modeled the long-term clinical and economic impact of two-dose universal varicella vaccination (UVV) strategies in Denmark using a dynamic transmission model. The cost-effectiveness of UVV was evaluated along with the impact on varicella (including age-shift) and herpes zoster burden. Six two-dose UVV strategies were compared to no vaccination, at either short (12/15 months) or medium (15/48 months) intervals. Monovalent vaccines (V-MSD or V-G…
No prominent works on this page.
Universal varicella vaccination in Denmark
We modeled the long-term clinical and economic impact of two-dose universal varicella vaccination (UVV) strategies in Denmark using a dynamic transmission model. The cost-effectiveness of UVV was evaluated along with the impact on varicella (including age-shift) and herpes zoster burden. Six two-dose UVV strategies were compared to no vaccination, at either short (12/15 months) or medium (15/48 months) intervals. Monovalent vaccines (V-MSD or V-G…
Economic burden of varicella in Bangkok, Thailand
Our multicenter, medical chart review, cost-of-illness study used a micro-costing approach to evaluate the economic burden associated with varicella in Bangkok, Thailand, from a societal perspective. We reviewed medical charts of adults and children with a primary diagnosis of varicella (2014–2018) from 4 hospitals in Bangkok. Reported healthcare resource utilization and missed school or workdays were extracted from medical charts. Mean direct, i…
Modeling the clinical and economic impact of universal varicella vaccination in Belgium with dynamic population
Although universal varicella vaccination (UVV) significantly reduces morbidity and mortality, it has not been implemented in Belgium. We evaluated the clinical and economic outcomes of two-dose UVV in Belgium. A previously published dynamic transmission model with dynamic population age structure was adapted to Belgium. The base case UVV strategy (Strategy 0) consisted of routine two-dose varicella vaccination at ages 1 year (vaccine coverage rat…
Herpesvirus Infections and Treatments (3 works) · Hepatitis Viruses Studies and Epidemiology (2 works) · Medicine (2 works) · Pediatrics (2 works) · Vaccination (2 works) · Bartonella species infections research (1 work) · Chickenpox Vaccine (1 work) · Cost–benefit analysis (1 work) · Cumulative incidence (1 work) · Cytomegalovirus and herpesvirus research (1 work)